MA49563A - Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôle - Google Patents
Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôleInfo
- Publication number
- MA49563A MA49563A MA049563A MA49563A MA49563A MA 49563 A MA49563 A MA 49563A MA 049563 A MA049563 A MA 049563A MA 49563 A MA49563 A MA 49563A MA 49563 A MA49563 A MA 49563A
- Authority
- MA
- Morocco
- Prior art keywords
- control point
- bispecific antibodies
- point inhibitors
- inhibitors
- bispecific
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762530436P | 2017-07-10 | 2017-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49563A true MA49563A (fr) | 2020-05-20 |
Family
ID=63013165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049563A MA49563A (fr) | 2017-07-10 | 2018-07-09 | Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôle |
Country Status (26)
Country | Link |
---|---|
US (1) | US11203640B2 (fr) |
EP (1) | EP3652216A1 (fr) |
JP (1) | JP6953612B2 (fr) |
KR (1) | KR102309950B1 (fr) |
CN (1) | CN110914306B (fr) |
AR (1) | AR112603A1 (fr) |
AU (1) | AU2018301326B2 (fr) |
BR (1) | BR112020000162A2 (fr) |
CA (1) | CA3069254C (fr) |
CL (1) | CL2020000053A1 (fr) |
CO (1) | CO2019015100A2 (fr) |
CR (1) | CR20190576A (fr) |
EA (1) | EA201992757A1 (fr) |
IL (1) | IL271347B2 (fr) |
JO (1) | JOP20200003B1 (fr) |
MA (1) | MA49563A (fr) |
MX (1) | MX2020000242A (fr) |
MY (1) | MY195071A (fr) |
NZ (1) | NZ760683A (fr) |
PE (1) | PE20200297A1 (fr) |
PH (1) | PH12020500075A1 (fr) |
SG (1) | SG11201911817VA (fr) |
TW (1) | TWI714864B (fr) |
UA (1) | UA126032C2 (fr) |
WO (1) | WO2019014091A1 (fr) |
ZA (1) | ZA201908549B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY160203A (en) | 2009-03-30 | 2017-02-28 | Eisai R&D Man Co Ltd | Liposome composition |
EP3449921B1 (fr) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin pour l' inhibition de croissance tumorale |
IL265605B2 (en) | 2016-09-29 | 2024-06-01 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation |
TN2019000161A1 (en) | 2016-11-18 | 2020-10-05 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof |
EP3608341A4 (fr) * | 2017-04-01 | 2021-01-06 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anticorps bispécifique hétérodimère de type structure d'anticorps naturel anti-pd-l1/anti-pd-1 et sa préparation |
WO2019153200A1 (fr) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation |
CN112334488B (zh) * | 2018-07-19 | 2023-12-08 | 伊莱利利公司 | 靶向免疫检查点的双特异性抗体 |
TWI760751B (zh) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
WO2021143767A1 (fr) * | 2020-01-15 | 2021-07-22 | 信达生物制药(苏州)有限公司 | Préparation d'anticorps bispécifique combinant pd-1 et pd-l1 et son utilisation |
WO2021213523A1 (fr) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | Utilisations d'une combinaison d'anticorps anti-pd-1 et d'anticorps anti-ctla-4 dans la prévention ou le traitement du cancer |
WO2021226984A1 (fr) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | Anticorps bispécifique tétravalent contre pd-1 et pd-l1 |
JP2023116826A (ja) * | 2020-05-20 | 2023-08-23 | 中外製薬株式会社 | 抗原結合分子 |
CN113754773A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pd1×pdl1的双特异性抗体 |
US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
CN114601924A (zh) * | 2020-12-09 | 2022-06-10 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法 |
WO2023020315A1 (fr) * | 2021-08-19 | 2023-02-23 | 南京吉盛澳玛生物医药有限公司 | Anticorps ciblant pd-l1/pd-1 et son utilisation |
CN118103067A (zh) * | 2021-09-14 | 2024-05-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和化疗药的药物组合及其使用方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
EP3050963B1 (fr) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble |
EP1999154B1 (fr) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Domaines de proteine heterodimerique d'ingenierie |
WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
EP2235064B1 (fr) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
WO2010129304A2 (fr) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Procédé de fabrication de molécules hétéromultimères |
US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
KR20120125611A (ko) | 2009-12-29 | 2012-11-16 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 이종이량체 결합 단백질 및 이의 용도 |
JP2013523098A (ja) | 2010-03-29 | 2013-06-17 | ザイムワークス,インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
CA2811323C (fr) | 2010-09-24 | 2019-01-15 | Zymeworks Inc. | Systeme pour calculs de structures moleculaires |
AU2011308042B2 (en) | 2010-09-30 | 2015-07-16 | Zymeworks Inc. | Simplifying residue relationships in protein design |
DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
DK2681245T3 (en) | 2011-03-03 | 2018-08-13 | Zymeworks Inc | MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS |
HRP20211773T1 (hr) | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
KR20150008171A (ko) | 2012-05-10 | 2015-01-21 | 자임워크스 인코포레이티드 | 단일군 일가 항체 구조물 및 그의 용도 |
JP6498601B2 (ja) | 2012-07-13 | 2019-04-10 | ザイムワークス,インコーポレイテッド | 多価ヘテロ多量体足場設計および構築物 |
KR20150036606A (ko) | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체 |
US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
CN105121630B (zh) | 2012-10-03 | 2018-09-25 | 酵活有限公司 | 定量重链和轻链多肽对的方法 |
AU2013337578C1 (en) | 2012-11-02 | 2018-04-12 | Zymeworks Inc. | Crystal structures of heterodimeric Fc domains |
AU2013351888C1 (en) | 2012-11-28 | 2018-10-11 | Zymeworks Bc Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
BR112016016114A2 (pt) | 2014-01-15 | 2018-05-22 | Zymeworks Inc | Construtos de ligação a antígeno cd19 e cd3 bi- específico. |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015181805A1 (fr) | 2014-05-28 | 2015-12-03 | Zymeworks Inc. | Constructions modifiées de polypeptide de liaison à un antigène et leurs utilisations |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
US11001628B2 (en) * | 2015-07-29 | 2021-05-11 | Novartis Ag | Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer |
WO2017024465A1 (fr) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
WO2017087547A1 (fr) | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Agents de liaison à pd-l1 et leurs utilisations |
-
2018
- 2018-06-26 AR ARP180101760 patent/AR112603A1/es unknown
- 2018-06-27 TW TW107121984A patent/TWI714864B/zh active
- 2018-07-09 US US16/029,979 patent/US11203640B2/en active Active
- 2018-07-09 CN CN201880045977.1A patent/CN110914306B/zh active Active
- 2018-07-09 BR BR112020000162-7A patent/BR112020000162A2/pt unknown
- 2018-07-09 MY MYPI2020000114A patent/MY195071A/en unknown
- 2018-07-09 AU AU2018301326A patent/AU2018301326B2/en active Active
- 2018-07-09 JO JOP/2020/0003A patent/JOP20200003B1/ar active
- 2018-07-09 KR KR1020207000726A patent/KR102309950B1/ko active IP Right Grant
- 2018-07-09 UA UAA201912223A patent/UA126032C2/uk unknown
- 2018-07-09 JP JP2020500803A patent/JP6953612B2/ja active Active
- 2018-07-09 CA CA3069254A patent/CA3069254C/fr active Active
- 2018-07-09 NZ NZ760683A patent/NZ760683A/en unknown
- 2018-07-09 EA EA201992757A patent/EA201992757A1/ru unknown
- 2018-07-09 IL IL271347A patent/IL271347B2/en unknown
- 2018-07-09 MA MA049563A patent/MA49563A/fr unknown
- 2018-07-09 WO PCT/US2018/041205 patent/WO2019014091A1/fr active Search and Examination
- 2018-07-09 PE PE2019002612A patent/PE20200297A1/es unknown
- 2018-07-09 CR CR20190576A patent/CR20190576A/es unknown
- 2018-07-09 SG SG11201911817VA patent/SG11201911817VA/en unknown
- 2018-07-09 EP EP18745803.9A patent/EP3652216A1/fr active Pending
- 2018-07-09 MX MX2020000242A patent/MX2020000242A/es unknown
-
2019
- 2019-12-20 ZA ZA2019/08549A patent/ZA201908549B/en unknown
- 2019-12-30 CO CONC2019/0015100A patent/CO2019015100A2/es unknown
-
2020
- 2020-01-08 CL CL2020000053A patent/CL2020000053A1/es unknown
- 2020-01-09 PH PH12020500075A patent/PH12020500075A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49563A (fr) | Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôle | |
MA45255A (fr) | Anticorps inhibiteurs de points de contrôle bispécifiques | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
MA43028A (fr) | Anticorps bispécifiques pour pd1 et tim3 | |
MA53434A (fr) | Anticorps anti-tigit | |
MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA49043A (fr) | Formulation stable d'anticorps | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
MA44054A (fr) | Plateforme d'anticorps bispécifique | |
MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 |